Grant: Engage Grants Program
Université de Sherbrooke
$24,973.00
Effects of Bio-K+ probiotics on intestinal antimicrobial peptides and immunoglobulin production and their impact in bacterial infections associated to traveller's diarrhea
EF 2016-17
Résumé
Probiotics are a widely recognized natural approach to improve the general gastrointestinal health. Manybrands, based on many different microbial strains are currently on the market, with various degrees of successin applications ranging from a ""healthy daily supplement"" up to more targeted uses such as protection fromantibiotic-induced diarrhea. In this regard, the probiotics produced by Bio-K Plus International Inc. (Laval,Canada) have demonstrated to help reducing antibiotic-induced diarrhea and Clostridium difficile infections.These remarkable findings also hint at the possibility that Bio-K+ probiotics might be effective in preventing orattenuating other bacterial infections of the gastrointestinal system. However, this is still unclear. In addition,as it is the case for most probiotic products, there is little information on how Bio-K+ proprietary strains exerttheir beneficial effects on the gastrointestinal system.We will use a mouse model of probiotics administration to study how Bio-K+ strains impact the secretion ofintestinal immunoglobulins and the synthesis of intestinal antimicrobial peptides, two components of theenteric immune system critical for the proper functioning of the gastrointestinal tract and for the defenseagainst intestinal infections. Moreover, using animal models of bacterial infection, we will evaluate the abilityof Bio-K+ probiotics to prevent or attenuate gastroenteritis induced by Escherichia coli and Salmonellatyphimurium. These two bacterial pathogens are responsible for a number of diarrhea cases within Canada butmore significantly, they are among the leading causes of traveller's diarrhea. Every year, millions of Canadiansgo abroad and with current estimates of diarrhea affecting up to 60% of travellers, it is likely that the number oftraveller's diarrhea cases among Canadians runs very high. The results from this study will define the activity ofBioK+ probiotics against these two important bacterial pathogens and will help to formulate scientificallybased guidelines for the use of BioK+ probiotics to protect from traveller's diarrhea. The results will bepotentially beneficial for both Canadian public health and economic growth.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
500756-2016
Name nom
Menendez, Alfredo
Department département
Microbiologie et d'infectiologie
Organization id
68
Institution établissement
Université de Sherbrooke
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2016
Award amount
24973
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
5204
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Immunology
Research subject fr
Immunologie
Partie
1
Nb partie
1
Application title
Effects of Bio-K+ probiotics on intestinal antimicrobial peptides and immunoglobulin production and their impact in bacterial infections associated to traveller's diarrhea
Keyword
NSERC
Application summary
Probiotics are a widely recognized natural approach to improve the general gastrointestinal health. Manybrands, based on many different microbial strains are currently on the market, with various degrees of successin applications ranging from a ""healthy daily supplement"" up to more targeted uses such as protection fromantibiotic-induced diarrhea. In this regard, the probiotics produced by Bio-K Plus International Inc. (Laval,Canada) have demonstrated to help reducing antibiotic-induced diarrhea and Clostridium difficile infections.These remarkable findings also hint at the possibility that Bio-K+ probiotics might be effective in preventing orattenuating other bacterial infections of the gastrointestinal system. However, this is still unclear. In addition,as it is the case for most probiotic products, there is little information on how Bio-K+ proprietary strains exerttheir beneficial effects on the gastrointestinal system.We will use a mouse model of probiotics administration to study how Bio-K+ strains impact the secretion ofintestinal immunoglobulins and the synthesis of intestinal antimicrobial peptides, two components of theenteric immune system critical for the proper functioning of the gastrointestinal tract and for the defenseagainst intestinal infections. Moreover, using animal models of bacterial infection, we will evaluate the abilityof Bio-K+ probiotics to prevent or attenuate gastroenteritis induced by Escherichia coli and Salmonellatyphimurium. These two bacterial pathogens are responsible for a number of diarrhea cases within Canada butmore significantly, they are among the leading causes of traveller's diarrhea. Every year, millions of Canadiansgo abroad and with current estimates of diarrhea affecting up to 60% of travellers, it is likely that the number oftraveller's diarrhea cases among Canadians runs very high. The results from this study will define the activity ofBioK+ probiotics against these two important bacterial pathogens and will help to formulate scientificallybased guidelines for the use of BioK+ probiotics to protect from traveller's diarrhea. The results will bepotentially beneficial for both Canadian public health and economic growth.